APOE ε4携带者在多种神经退行性疾病中共享免疫相关蛋白质组改变
利用全球神经变性蛋白质组学联盟SomaScan数据集(1,346份脑脊液和9,924份血浆样本),通过机器学习蛋白质组分析,识别出APOE ε4在阿尔茨海默病、额颞叶痴呆、帕金森病痴呆、帕金森病、肌萎缩侧索硬化及非受损对照中共享的蛋白质组特征,该特征富集促炎免疫和感染通路及免疫细胞。对262名供者背外侧前额叶皮质蛋白质组的分析显示一致的APOE ε4表型,独立于神经退行性病理。APOE ε4相关促炎免疫特征持续存在于脑、脑脊液和血浆中,提示其赋予系统性生物学脆弱性,是神经退行性变的必要非充分条件。
要点
- APOE ε4在多种神经退行性疾病中共享促炎免疫和感染通路富集的蛋白质组特征。
- 该特征涉及单核细胞、T细胞和自然杀伤细胞等免疫细胞。
- APOE ε4相关免疫特征在脑、脑脊液和血浆中持续存在,与疾病类型无关。
核心结论
- APOE ε4赋予一种系统性生物学脆弱性,是神经退行性变的必要但非充分条件,强调需考虑基因-环境相互作用。
- 研究将APOE ε4重新定义为多效性免疫调节因子而非AD特异性风险基因,为跨神经退行性疾病的精准生物标志物开发和早期干预策略提供基础。
研究设计与样本
- 使用全球神经变性蛋白质组学联盟SomaScan数据集,覆盖1,346份脑脊液和9,924份血浆样本。
- 采用基于机器学习的蛋白质组分析识别APOE ε4蛋白质组特征。
- 分析加速医学伙伴关系AD UPenn蛋白质组学研究262名供者的背外侧前额叶皮质蛋白质组。
主要发现
- APOE ε4蛋白质组特征在AD、FTD、PDD、PD、ALS及非受损对照中共享,富集促炎免疫和感染通路以及单核细胞、T细胞和自然杀伤细胞。
- 背外侧前额叶皮质蛋白质组显示一致的APOE ε4表型,独立于神经退行性病理,包括所有疾病的淀粉样蛋白-β、tau和胶质增生,以及ALS和FTD病例的TDP-43和PD与PDD病例的α-突触核蛋白。
- APOE ε4携带者的系统性蛋白质组变化一致,但其与高血压和吸烟等临床和生活方式因素的关系因疾病而异。
- APOE ε4相关促炎免疫特征持续存在于脑、脑脊液和血浆中,与神经退行性疾病无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The APOE ε4 genetic variant is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) and is increasingly being implicated in other neurodegenerative diseases. Using the Global Neurodegeneration Proteomics Consortium SomaScan dataset covering 1,346 cerebrospinal fluid (CSF) and 9,924 plasma samples, we used machine learning-based proteome profiling to identify an APOE ε4 proteomic signature shared across individuals with AD, frontotemporal dementia (FTD), Parkinson's disease dementia (PDD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and nonimpaired controls. This signature was enriched in pro-inflammatory immune and infection pathways as well as immune cells, including monocytes, T cells and natural killer cells. Analysis of the dorsolateral prefrontal cortex proteome for 262 donors from the Accelerating Medicines Partnership for AD UPenn Proteomics Study revealed a consistent APOE ε4 phenotype, independent of neurodegenerative pathology, including amyloid-β tau and gliosis for all diseases, as well as TDP-43 in ALS and FTD cases, and α-synuclein in PD and PDD cases. While systemic proteomic changes were consistent across APOE ε4 carriers, their relationship with clinical and lifestyle factors, such as hypertension and smoking, varied by disease. These findings suggest APOE ε4 confers a systemic biological vulnerability that is necessary but not sufficient for neurodegeneration, emphasizing the need to consider gene-environment interactions. Overall, our study reveals a conserved APOE ε4-associated pro-inflammatory immune signature persistent across the brain, CSF and plasma irrespective of neurodegenerative disease, highlighting a fundamental, disease-independent biological vulnerability to neurodegeneration. This work reframes APOE ε4 as a pleiotropic immune modulator rather than an AD-specific risk gene, providing a foundation for precision biomarker development and early intervention strategies across neurodegenerative diseases.
引用
- Shvetcov A, Johnson ECB, Winchester LM, et al. APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases. Nat Med. 2025. PMID: 40665049. doi:10.1038/s41591-025-03835-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。